REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
REGENXBIO (RGNX) has scheduled a conference call for Thursday, March 13, at 4:30 p.m. ET to present its fourth quarter and full-year 2024 financial results along with recent operational updates. The presentation will be accessible through a webcast, with a dedicated link for analysts who wish to participate in the Q&A session. Participants are advised to join 15 minutes before the start time, and a replay will be made available on the company's investor website approximately two hours after the call concludes.
REGENXBIO (RGNX) ha programmato una conferenza telefonica per giovedì 13 marzo, alle 16:30 ET, per presentare i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024, insieme agli aggiornamenti operativi recenti. La presentazione sarà accessibile tramite un webcast, con un link dedicato per gli analisti che desiderano partecipare alla sessione di domande e risposte. Si consiglia ai partecipanti di unirsi 15 minuti prima dell'orario di inizio, e una registrazione sarà disponibile sul sito web per gli investitori della società circa due ore dopo la conclusione della chiamata.
REGENXBIO (RGNX) ha programado una conferencia telefónica para el jueves 13 de marzo a las 4:30 p.m. ET para presentar sus resultados financieros del cuarto trimestre y del año completo 2024, junto con actualizaciones operativas recientes. La presentación será accesible a través de un webcast, con un enlace dedicado para los analistas que deseen participar en la sesión de preguntas y respuestas. Se aconseja a los participantes unirse 15 minutos antes de la hora de inicio, y una repetición estará disponible en el sitio web de inversores de la compañía aproximadamente dos horas después de que finalice la llamada.
REGENXBIO (RGNX)는 3월 13일 목요일 오후 4시 30분 ET에 2024년 4분기 및 연간 재무 결과와 최근 운영 업데이트를 발표하기 위한 전화 회의를 예정했습니다. 발표는 웹캐스트를 통해 접근할 수 있으며, Q&A 세션에 참여하고자 하는 분석가를 위한 전용 링크가 제공됩니다. 참가자는 시작 15분 전에 접속할 것을 권장하며, 통화가 종료된 후 약 2시간 이내에 회사의 투자자 웹사이트에서 재생이 가능할 것입니다.
REGENXBIO (RGNX) a programmé une conférence téléphonique pour le jeudi 13 mars à 16h30 ET afin de présenter ses résultats financiers du quatrième trimestre et de l'année 2024, ainsi que des mises à jour opérationnelles récentes. La présentation sera accessible via un webcast, avec un lien dédié pour les analystes souhaitant participer à la session de questions-réponses. Les participants sont invités à se connecter 15 minutes avant l'heure de début, et un enregistrement sera disponible sur le site web des investisseurs de la société environ deux heures après la fin de l'appel.
REGENXBIO (RGNX) hat eine Telefonkonferenz für Donnerstag, den 13. März, um 16:30 Uhr ET angesetzt, um seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 sowie aktuelle betriebliche Updates zu präsentieren. Die Präsentation wird über ein Webcast zugänglich sein, mit einem speziellen Link für Analysten, die an der Q&A-Sitzung teilnehmen möchten. Teilnehmer werden gebeten, 15 Minuten vor Beginn der Veranstaltung beizutreten, und eine Wiederholung wird etwa zwei Stunden nach Abschluss des Anrufs auf der Investorenseite des Unternehmens verfügbar sein.
- None.
- None.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-march-13-to-discuss-fourth-quarter-and-full-year-2024-financial-results-and-recent-operational-highlights-302385846.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO (RGNX) reporting Q4 and full-year 2024 earnings?
How can investors access RGNX's Q4 2024 earnings call?
Will there be a replay available for RGNX's Q4 2024 earnings call?
What time should participants join RGNX's Q4 2024 earnings call?
